

\*\*\*\*Published November 2019\*\*\*\*

## MarketVIEW: Lassa fever vaccines (CAT: VAMV080)

<b>Product Name</b>	:	<b>MarketVIEW: Lassa fever vaccines</b>
<b>Description</b>	:	Global vaccine commercial opportunity assessment
<b>Contents</b>	:	Executive presentation (~140 slides.pdf) + MS-Excel forecast model(s) (.xls)
<b>Therapeutic Area</b>	:	Novel viral vaccines
<b>Publication date</b>	:	November 2019
<b>Catalogue No</b>	:	VAMV080

## Background

**Lassa fever** is an acute viral hemorrhagic illness caused by **Lassa virus (LASV)**, a single-stranded RNA virus of the *Arenaviridae* family. The virus is zoonotic and mainly transmitted from the host, *M natalensis* (multimammate rat) to humans where it can cause symptoms ranging from fever, general malaise, weakness, and headache to the more serious outcomes of multi-organ failure or death. A significant cause of morbidity in survivors is deafness (which can be permanent) and occurs in approximately one-third of cases.

It is estimated that there are between 100,000 and 300,000 Lassa fever infections in West Africa per year, resulting in approximately 5,000 deaths, although estimates are outdated and impacted by a lack of routine surveillance. An epidemic continues to increase in certain parts of Nigeria. Intravenous ribavirin (if given early) can reduce mortality. There are a number of prophylactic Lassa fever vaccines in pre-clinical and now clinical development supported by CEPI/WHO initiatives.

This **MarketVIEW** product is a comprehensive Executive Presentation (~140 slides) and MS-Excel forecast model which investigates the commercial potential of a putative Lassa fever vaccine in all relevant target groups (preventative and emergency scenarios) to 2030. There is a detailed case study analysis of **Ebola vaccine** procurement/deployment to serve as guidance with all assumptions clearly outlined. A thorough review of current disease background/epidemiology and R&D competitive environment are also included. This product is ideally suited to organisations wishing to quantify the Lassa fever vaccine opportunity.

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to Lassa fever vaccines in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of viral based-pathogens, especially Ebola virus has also been utilised.

### PRODUCT CONTENTS:

Published November 2019 (CAT No: VAMV080)

\*\*\*\*This product is a [summary presentation \(.pdf\)](#), [a forecast model \(.xls\)](#)

#### Contents – Summary presentation (.pdf)<sup>1</sup>

Contents  
Author's notes  
Executive summary  
**[SECTION 1]** Lassa fever vaccines: key commercial model outputs  
**[SECTION 2]** Lassa fever: disease background  
**[SECTION 3]** Lassa fever: epidemiology  
**[SECTION 4]** Lassa fever: summary of vaccine development  
**[SECTION 5]** Lassa fever vaccines: modelling commercial potential  
About **VacZine Analytics**  
Disclaimer



**SNAPSHOT**

**PAGES: ~140 slides** fully referenced/sourced. Available in .pdf form

#### Contents – Vaccine demand model (MS Excel-based)

**Worksheets = >30 interconnected**

---

<sup>1</sup> Full contents i.e. title per slide is available upon request

**PRODUCT COST:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8,995.00**/ GBP **£7,000**<sup>#</sup> (Region license)\*

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

*# - indicative prevailing rate will be applied on date of transaction, third-party licenses may be restricted/vary*

**HOW TO ORDER:**

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com) This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.




**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and the “spiral logo” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY

References – available upon request



**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**

A division of Assay Advantage Ltd

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 927049

E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics** ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** ® and “the spiral logo” are UK Registered Trademarks, 2009

